(e,z)-farnesol

(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Osteosarcoma D012516 50 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fibrosis D005355 23 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Hypergammaglobulinemia D006942 9 associated lipids
Glioblastoma D005909 27 associated lipids
Nephritis D009393 19 associated lipids
HIV Infections D015658 20 associated lipids
Neurilemmoma D009442 10 associated lipids
Per page 10 20 50 | Total 23

PubChem Biomolecular Interactions and Pathways

All references with (e,z)-farnesol

Download all related citations
Per page 10 20 50 100 | Total 813
Authors Title Published Journal PubMed Link
Gomes F et al. Farnesol as antibiotics adjuvant in Staphylococcus epidermidis control in vitro. 2011 Am. J. Med. Sci. pmid:21107231
Huang J et al. Electrohydrodynamic deposition of nanotitanium doped hydroxyapatite coating for medical and dental applications. 2011 J Mater Sci Mater Med pmid:21243517
Bai C et al. Characterization of a hyperactive Cyr1 mutant reveals new regulatory mechanisms for cellular cAMP levels in Candida albicans. 2011 Mol. Microbiol. pmid:21992526
Piispanen AE et al. Roles of Ras1 membrane localization during Candida albicans hyphal growth and farnesol response. 2011 Eukaryotic Cell pmid:21908593
Biran A et al. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. 2011 Int. J. Cancer pmid:20473860
Fong C et al. Monodisperse nonionic isoprenoid-type hexahydrofarnesyl ethylene oxide surfactants: high throughput lyotropic liquid crystalline phase determination. 2011 Langmuir pmid:21294552
Bendena WG et al. Evidence for differential biosynthesis of juvenile hormone (and related) sesquiterpenoids in Drosophila melanogaster. 2011 Gen. Comp. Endocrinol. pmid:21354154
Rahman NK et al. Enzymatic synthesis of farnesyl laurate in organic solvent: initial water activity, kinetics mechanism, optimization of continuous operation using packed bed reactor and mass transfer studies. 2011 Bioprocess Biosyst Eng pmid:21327986
Madhani HD Quorum sensing in fungi: Q&A. 2011 PLoS Pathog. pmid:22046125
Pammi M et al. Farnesol decreases biofilms of Staphylococcus epidermidis and exhibits synergy with nafcillin and vancomycin. 2011 Pediatr. Res. pmid:21857375
Goto T et al. Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways. 2011 Am. J. Physiol. Endocrinol. Metab. pmid:21862726
Ganguly S et al. Zap1 control of cell-cell signaling in Candida albicans biofilms. 2011 Eukaryotic Cell pmid:21890817
Pando R et al. The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat. 2010 Mar-Apr Cardiovasc. Pathol. pmid:19144546
Gilpin S and Maibach H Allergic contact dermatitis caused by farnesol: clinical relevance. 2010 Cutan Ocul Toxicol pmid:20858058
Aizman E et al. The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. 2010 J. Neuroimmunol. pmid:20869125
Kubesová A et al. Separation of attogram terpenes by the capillary zone electrophoresis with fluorometric detection. 2010 J Chromatogr A pmid:20933239
Eglin D et al. Farnesol-modified biodegradable polyurethanes for cartilage tissue engineering. 2010 J Biomed Mater Res A pmid:19191318
Langford ML et al. Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions. 2010 Antimicrob. Agents Chemother. pmid:19933803
Yaari-Stark S et al. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. 2010 Int. J. Cancer pmid:19998334
Deveau A et al. Farnesol induces hydrogen peroxide resistance in Candida albicans yeast by inhibiting the Ras-cyclic AMP signaling pathway. 2010 Eukaryotic Cell pmid:20118211

Table of Content